<DOC>
	<DOCNO>NCT01072903</DOCNO>
	<brief_summary>The research project address follow hypothesis ( A ) normal balance beneficial detrimental commensal intestinal bacteria derange IBS , selective alteration clinically define patient subset i.e. , diarrhea predominant IBS ( D-IBS ) post-infectious IBS ( PI-IBS ) ; ( B ) change intestinal microflora associate sub-clinical mucosal inflammation activation mucosal immune system ; ( C ) activation mucosal immune system lead alteration gastrointestinal ( GI ) function ( i.e. , motility sensation ) functional symptom .</brief_summary>
	<brief_title>The Role Intestinal Inflammation Irritable Bowel Syndrome ( IBS )</brief_title>
	<detailed_description>There two main aim research study . The first aim determine whether sub-clinical mucosal inflammation occur patient D-IBS identifying alteration mucosal marker inflammation ( inflammatory cytokine inflammation-related mediator ) . The second aim investigate whether identifiable alteration inflammatory marker associate specific abnormality intestinal motor sensory function relevant pathophysiology IBS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Colonic Diseases</mesh_term>
	<mesh_term>Colonic Diseases , Functional</mesh_term>
	<criteria>Any sex , race , ethnicity . At least 18 year age ( upper age limit ) . DIBS MIBS patient must meet Rome II criterion IBS must evaluate physician exclude alternative disease could explain symptom . For latter , patient ' self statement acceptable ( selfreport , official document require ) . DIBS MIBS subject old 50 year old must colonoscopy past 5 year normal report . Hemorrhoids , diverticulosis polyp allow . Participation Dr. Whitehead 's heterogeneity IBS research study , Dr. Ringel 's Probiotic Pain Study . Healthy control must significant recur gastrointestinal symptom . Patients healthy control serious , unstable medical condition . Patients healthy control must gastrointestinal tract surgery appendectomy cholecystectomy , abdominal surgery within past 3 month . Appendectomy cholecystectomy allow do 2 year ago symptom change follow surgery . Pregnancy breastfeeding ( selfreport ) . No history inflammatory bowel disease , celiac disease , diagnosis could explain chronic recur bowel symptom IBS patient control ( selfreport ) . Patients control history lactose malabsorption ( selfreport ) . Patients control history clinical symptom acute infection last 8 week prior enrollment study . Patients control history antiinflammatory agent include aspirin , nonaspirin , nonsteroid antiinflammatory ( NSAID ) , steroid , antibiotic , probiotic treatment last 4 week prior enrollment study . Patients implant portable electromechanical medical device pacemaker and/or implant stimulators pump . Evidence acute inflammation routine histology . Evidence enteric pathogen routine stool culture . Presence medical condition require routine use antibiotic treatment dental invasive procedure ( selfreport ) . To confirmed time screen week flexible sigmoidoscopy appointment IBSM subject ONLY : In past week , subject less 3 ( 02 ) bowel movement . Also , past week , subject hard/lumpy stool 2 day . Only subject IBS may participate optional SmartPill test . Subjects exclude SmartPill test subject : A history gastric bezoar . Suspected stricture , fistula , colon cancer physiological GI obstruction . Dysphagia . Diverticulitis . Tobacco use within eight hour prior capsule ingestion initial 8 hour record Day 0 Ingestion visit . Alcohol use within eight hour prior capsule ingestion throughout entire monitoring period ( 5 day ) . Body Mass Index &gt; 40 kg/m2 . Female childbearing age practice birth control and/or pregnant lactating . Cardiovascular , endocrine , renal , chronic disease likely affect motility . A medical device pacemaker , infusion pump , insulin pump . Any contraindication use Fleets Enema balloon expulsion test . Uncontrolled diabetes hemoglobin A1C great 10 . Allergies ingredients standard SmartBar meal Subject plan take follow prohibit medication : Medication alter gastric pH , Medication affect GI motility 3 full day start study ensue day study , Medication nausea vomit block serotonin receptor , Antidiarrheal agent , Opiate agent use treat diarrhea , Nonsteroidal antiinflammatory drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>inflammation</keyword>
	<keyword>colon , irritable</keyword>
	<keyword>Colonic Diseases , Functional</keyword>
	<keyword>Irritable Bowel Syndrome</keyword>
</DOC>